Regeneron CEO Leonard Schleifer, MD, PhD, reportedly suggested changing Medicare to add an out-of-pocket cap as a way to bring down costs.
Pfizer CEO Albert Bourla, PhD, suggested passing rebates paid to pharmacy benefit managers through to consumers and said the current system drives up list prices and out-of pocket costs.
Executives also blamed hospitals and insurers for high drug costs, according to CNBC. Bristol-Myers Squibb CEO Giovanni Caforio, MD, and Roche CEO Bill Anderson both reportedly blamed hospitals for marking up drug costs.
Eli LIlly CEO David Ricks blamed health insurers for expensive drugs, arguing they ultimately determine what patients pay.
The executives seemed to agree that something needed to be done legislatively to lower costs for seniors using Medicare, but also argued that the cost of drugs represented only a small fraction of overall costs in the U.S. healthcare system.
Read the full article here.
More articles on pharmacy:
CVS to add 600 HealthHUBs, link them to lower Aetna copays
Civica Rx calls on generic drugmakers to donate to its cause
Pfizer, GlaxoSmithKline give timeline for IPO of joint venture
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.